rolapitant profile

ID Source	ID
PubMed CID	10311306
CHEMBL ID	3707331
CHEBI ID	90908
SCHEMBL ID	354305
MeSH ID	M0582062

Synonym
varubi (tn)
sch 619734
varubi
8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one
552292-08-7
rolapitant ,
sch-619734
unii-nle429izuc
nle429izuc ,
rolapitant [usan:inn]
(5s,8s)-8-(((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4.5)decan-2-one
(5s,8s)-8-(((r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
S5476
gtpl5749
(5s,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
varuby
rolapitant [mi]
1,7-diazaspiro(4.5)decan-2-one, 8-(((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, (5s,8s)-
(5s,8s)-8-{[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl}-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
rolapitant [inn]
rolapitant [usan]
rolapitant [who-dd]
SCHEMBL354305
(5s,8s)-8-({(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
CHEBI:90908 ,
CHEMBL3707331
rolapitant (usan/inn)
D10742
AC-30924
bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
DTXSID90203740 ,
DB09291
EX-A1288
rolapitant(sch619734)
AKOS030234023
rolapitant free base
mfcd23105917
HY-14751
CS-6387
5552292-08-7 (free base)
BCP09609
CCG-269691
MS-29288
brand name: varubi
sch619734 sch-619734
EN300-18166845
fivsjygqaiemoc-zgnkegeesa-n
dtxcid20126231
a04ad14
rolapitantum

Research Excerpts

Overview

Rolapitant is a highly selective neurokinin-1 receptor antagonist. orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2-4.

Excerpt	Reference	Relevance
"Rolapitant is a functionally competitive antagonist, as measured by calcium efflux, with a calculated Kb of 0.17 nM."	( Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Duffy, RA; Higgins, GA; Lachowicz, JE; Morgan, C; Naylor, R; Parker, EM; Varty, GB, 2012)	2.54
"Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2-4. "	( Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). Abdel-Rahman, O; Rashad, N, 2017)	2.17
"Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist with very good oral activity, central nervous system penetration and a long (180-hour) plasma half-life."	( Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting. Rapoport, BL, 2017)	2.62
"Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. "	( Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers. Arora, S; Christensen, J; Hughes, L; Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY, 2018)	2.31
"Rolapitant is a novel selective neurokinin-1 receptor antagonist (NK-1 RA), which was clinically approved for prevention of CINV."	( Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Hammad, AM; Negida, A; Salem, M; Zidan, M, )	1.12
"Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. "	( Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment. Arora, S; Kansra, V; Lu, S; Wang, J; Wang, X; Zhang, ZY, 2018)	2.25
"Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with dexamethasone and a 5-hydroxytryptamine type 3 receptor antagonist for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. "	( Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects. Arora, S; Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY, 2019)	2.21
"Rolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting (CINV) associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy. "	( Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects. Kansra, V; Wang, J; Wang, X; Zhang, ZY, 2019)	2.2
"Rolapitant is a neurokinin-1 receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed chemotherapy-induced nausea and vomiting. "	( Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY, 2019)	2.35
"Rolapitant (Varubi) is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced nausea and vomiting. "	( Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects. Arora, S; Christensen, J; Hughes, L; Lu, S; Wang, J; Wang, X; Zhang, ZY, 2019)	2.24
"Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist. "	( Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015)	2.28
"Rolapitant (Varubi™) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. "	( Rolapitant: first global approval. Syed, YY, 2015)	3.3
"Rolapitant is a long-acting NK-1 receptor antagonist with proven efficacy in controlling CINV as part of the prophylaxis regimen."	( Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence. Chasen, MR; Rapoport, BL, 2016)	2.6

Toxicity

Rolapitant was safe and well tolerated across all studies. The most frequently reported treatment-related treatment-emergent adverse events were fatigue, constipation, and headache.

Excerpt	Reference	Relevance
"Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days after treatment."	( Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled Arora, S; Chasen, MR; Gridelli, C; Modiano, MR; Navari, RM; Poma, A; Rapoport, BL; Schnadig, ID; Schwartzberg, LS; Urban, L, 2015)	0.73
" The incidence of adverse events was similar in the rolapitant and control groups, with the most frequently reported treatment-related treatment-emergent adverse events being fatigue, constipation, and headache."	( Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled Arora, S; Chasen, MR; Gridelli, C; Modiano, MR; Navari, RM; Poma, A; Rapoport, BL; Schnadig, ID; Schwartzberg, LS; Urban, L, 2015)	0.98
" The incidence of adverse events was similar across treatment groups."	( Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Arora, S; Chasen, MR; Gridelli, C; Kansra, V; Modiano, MR; Navari, RM; Poma, A; Rapoport, BL; Schnadig, ID; Schwartzberg, LS; Urban, L, 2015)	0.73
" The incidence of treatment-related adverse events during cycles 2-6 was similar in rolapitant (5."	( Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016)	0.97
" To analyze potential drug-drug interactions between rolapitant and concomitant medications, this integrated safety analysis of four double-blind, randomized phase II or III studies of rolapitant examined adverse events (AEs) by use versus non-use of drug substrates of CYP2D6 or BCRP."	( Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant. Aapro, M; Arora, S; Barbour, S; Herrstedt, J; Kansra, V; Powers, D; Smit, T; Wang, X, 2017)	0.99
" Rolapitant was safe and well tolerated across all studies, with no serious or severe rolapitant-related treatment-emergent adverse events."	( Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects. Arora, S; Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY, 2019)	1.68

Pharmacokinetics

The pharmacokinetic and safety profiles of intravenous (IV) rolapitant were evaluated in two open-label, phase 1 trials in healthy subjects. This was a single oral dose of 180 mg of ro Lapitant and its major active metabolite, M19, in subjects with mild and moderate hepatic impairment compared with healthy matched controls.

Excerpt	Reference	Relevance
" This was a phase 1 open-label, parallel-group pharmacokinetic and safety study of a single oral dose of 180 mg of rolapitant and its major active metabolite, M19, in subjects with mild and moderate hepatic impairment compared with healthy matched controls."	( Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment. Arora, S; Kansra, V; Lu, S; Wang, J; Wang, X; Zhang, ZY, 2018)	1.01
" The pharmacokinetic and safety profiles of intravenous (IV) rolapitant were evaluated in two open-label, phase 1 trials in healthy subjects."	( Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects. Arora, S; Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY, 2019)	1.01
" Three phase 1, open-label, drug-drug interaction studies were conducted to examine the pharmacokinetic interactions of orally administered rolapitant with midazolam, rolapitant with ketoconazole, and rolapitant with rifampin."	( Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects. Arora, S; Christensen, J; Hughes, L; Lu, S; Wang, J; Wang, X; Zhang, ZY, 2019)	1
" Population pharmacokinetic analysis was performed via nonlinear mixed-effects modeling."	( Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting. Kansra, V; Wang, J; Wang, X; Zhang, ZY, 2019)	0.8

Bioavailability

Excerpt	Reference	Relevance
" Two studies in healthy volunteers evaluated 1) absolute bioavailability and 2) NK-1 receptor occupancy of oral rolapitant."	( Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers. Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY, 2017)	2.11

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
antiemetic	A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
neurokinin-1 receptor antagonist	An antagonist at the neurokinin-1 receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
ether	An organooxygen compound with formula ROR, where R is not hydrogen.
azaspiro compound	An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle.
pyrrolidin-2-ones	A pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
piperidines
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	26.2123	0.0052	9.4661	32.9993	AID1347411
Interferon beta	Homo sapiens (human)	Potency	26.2123	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Substance-P receptor	Homo sapiens (human)	Ki	0.0007	0.0000	0.7936	8.7470	AID1340842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
aggressive behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of leukocyte migration	Substance-P receptor	Homo sapiens (human)
angiotensin-mediated drinking behavior	Substance-P receptor	Homo sapiens (human)
inflammatory response	Substance-P receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Substance-P receptor	Homo sapiens (human)
tachykinin receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
long-term memory	Substance-P receptor	Homo sapiens (human)
associative learning	Substance-P receptor	Homo sapiens (human)
detection of abiotic stimulus	Substance-P receptor	Homo sapiens (human)
response to ozone	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell migration	Substance-P receptor	Homo sapiens (human)
response to auditory stimulus	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell migration	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, cholinergic	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Substance-P receptor	Homo sapiens (human)
response to estradiol	Substance-P receptor	Homo sapiens (human)
response to progesterone	Substance-P receptor	Homo sapiens (human)
response to nicotine	Substance-P receptor	Homo sapiens (human)
operant conditioning	Substance-P receptor	Homo sapiens (human)
sperm ejaculation	Substance-P receptor	Homo sapiens (human)
eating behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of vascular permeability	Substance-P receptor	Homo sapiens (human)
response to ethanol	Substance-P receptor	Homo sapiens (human)
positive regulation of action potential	Substance-P receptor	Homo sapiens (human)
positive regulation of blood pressure	Substance-P receptor	Homo sapiens (human)
positive regulation of ossification	Substance-P receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Substance-P receptor	Homo sapiens (human)
positive regulation of hormone secretion	Substance-P receptor	Homo sapiens (human)
behavioral response to pain	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of lymphocyte proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of stress fiber assembly	Substance-P receptor	Homo sapiens (human)
response to electrical stimulus	Substance-P receptor	Homo sapiens (human)
smooth muscle contraction involved in micturition	Substance-P receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Substance-P receptor	Homo sapiens (human)
positive regulation of flagellated sperm motility	Substance-P receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
tachykinin receptor activity	Substance-P receptor	Homo sapiens (human)
protein binding	Substance-P receptor	Homo sapiens (human)
substance P receptor activity	Substance-P receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
cell surface	Substance-P receptor	Homo sapiens (human)
dendrite	Substance-P receptor	Homo sapiens (human)
sperm flagellum	Substance-P receptor	Homo sapiens (human)
cell body	Substance-P receptor	Homo sapiens (human)
sperm head	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1346346	Human NK1 receptor (Tachykinin receptors)	2012	Pharmacology, biochemistry, and behavior, Jul, Volume: 102, Issue:1	Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	41 (89.13)	24.3611
2020's	5 (10.87)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	17 (33.33%)	5.53%
Reviews	14 (27.45%)	6.00%
Case Studies	1 (1.96%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (37.25%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, Double-Dummy, Dose-Ranging, Active- and Placebo-Controlled Study of Single-Dose Oral Rolapitant Monotherapy for the Prevention of Postoperative Nausea and Vomiting (PONV) [NCT00539721]	Phase 2	619 participants (Actual)	Interventional	2007-10-31	Completed
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant [NCT02285647]	Phase 1	138 participants (Actual)	Interventional	2014-09-30	Completed
Phase II Study of Rolapitant Plus Olanzapine, Palonosetron, and Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-day Cisplatin-based Chemotherapy. [NCT03960151]	Phase 2	0 participants (Actual)	Interventional	2018-05-31	Withdrawn(stopped due to Compound was sold by funder and development ceased.)
Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Idiopathic Cough [NCT00506545]	Phase 2	35 participants (Actual)	Interventional	2007-01-31	Completed
Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi®) Plus Ondansetron vs. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temo [NCT02991456]	Phase 2	48 participants (Actual)	Interventional	2017-10-09	Completed
A Phase 2, MultiCenter, Randomized, Placebo-Controlled, Double-Blind, Dose Finding Study to Determine the Safety and Efficacy of SCH 619734 for the Treatment of Chemotherapy Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemot [NCT00394966]	Phase 2	450 participants (Anticipated)	Interventional	2006-09-30	Completed
Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety & Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) [NCT01499849]	Phase 3	532 participants (Actual)	Interventional	2012-02-29	Completed
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers [NCT02382666]	Phase 1	100 participants (Actual)	Interventional	2015-01-31	Completed
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (1.8 mg/mL Rolapitant IV Solution) on the Pharmacokinetics of Digoxin (P-gp); Sulfasalazine (BCRP); and the Cooperstown Cocktail (Midazolam [CYP3A4], Omeprazole [CYP2C19], Wa [NCT02434861]	Phase 1	102 participants (Actual)	Interventional	2015-05-31	Completed
A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy [NCT01500213]	Phase 3	555 participants (Actual)	Interventional	2012-02-29	Completed
Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI) [NCT02732015]	Phase 2	37 participants (Actual)	Interventional	2016-10-12	Terminated(stopped due to Terminated per PI's request)
Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy [NCT01500226]	Phase 3	1,369 participants (Actual)	Interventional	2012-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT01499849 (3) [back to overview]	Acute Phase Response
NCT01499849 (3) [back to overview]	No Emetic Episodes and No Rescue Medication
NCT01499849 (3) [back to overview]	Overall Response Rate
NCT01500213 (3) [back to overview]	Acute Phase Response
NCT01500213 (3) [back to overview]	No Emetic Episodes and No Rescue Medication
NCT01500213 (3) [back to overview]	Overall Response Rate
NCT01500226 (3) [back to overview]	Acute Phase Response
NCT01500226 (3) [back to overview]	No Emetic Episodes and No Rescue Medication
NCT01500226 (3) [back to overview]	Overall Response Rate
NCT02732015 (1) [back to overview]	Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose
NCT02991456 (17) [back to overview]	Chemoradiation-induced Nausea (cRIN) Rate Over All Six Weeks
NCT02991456 (17) [back to overview]	Chemoradiation-induced Nausea (cRIN) Rate Over First Two Weeks
NCT02991456 (17) [back to overview]	Chemoradiation-induced Nausea (cRIN) Rate Over First Two Weeks and Supplemented by Nurses Notes
NCT02991456 (17) [back to overview]	Chemoradiation-induced Vomiting (cRIV) Rate Over All Six Weeks
NCT02991456 (17) [back to overview]	Chemoradiation-induced Vomiting (cRIV) Rate Over First Two Weeks
NCT02991456 (17) [back to overview]	Chemoradiation-induced Vomiting (cRIV) Rate Over First Two Weeks With Supplemental Nurses Notes
NCT02991456 (17) [back to overview]	Complete Response (CR) Rate as Measured by Antiemesis Tool (MAT)
NCT02991456 (17) [back to overview]	Complete Response (CR) Rate as Measured by MAT With Supplemental Nurses Notes
NCT02991456 (17) [back to overview]	Ondansetron Medication Compliance Weeks 1-3
NCT02991456 (17) [back to overview]	Ondansetron Medication Compliance Weeks 4-6
NCT02991456 (17) [back to overview]	Proportion of Participants With Grade 3, 4 or 5 Treatment-related Adverse Events
NCT02991456 (17) [back to overview]	Week 3 Patient Satisfaction: Convenience
NCT02991456 (17) [back to overview]	Week 3 Patient Satisfaction: Effectiveness
NCT02991456 (17) [back to overview]	Week 3 Patient Satisfaction: Overall Satisfaction
NCT02991456 (17) [back to overview]	Week 6 Patient Satisfaction: Convenience
NCT02991456 (17) [back to overview]	Week 6 Patient Satisfaction: Effectiveness
NCT02991456 (17) [back to overview]	Week 6 Patient Satisfaction: Overall Satisfaction

Acute Phase Response

To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours)phase of CINV (NCT01499849)
Timeframe: 0 to 24 hours

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	83.7
Placebo + Granisetron + Dexamethasone	73.7

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	72.7
Placebo + Granisetron + Dexamethasone	58.4

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	70.1
Placebo + Granisetron + Dexamethasone	56.5

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	83.4
Placebo + Granisetron + Dexamethasone	79.5

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	67.5
Placebo + Granisetron + Dexamethasone	60.4

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	83.5
Placebo + Granisetron + Dexamethasone	80.3

Intervention	percentage of particpants (Number)
Rolapitant + Granisetron + Dexamethasone	71.3
Placebo + Granisetron + Dexamethasone	61.6

Intervention	percentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone	68.6
Placebo + Granisetron + Dexamethasone	57.8

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carbamates [no description available]	3.59	1	1	amino-acid anion
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.21	1	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.59	1	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
lauric acid dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.	2.21	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; antibacterial agent; plant metabolite
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	3.59	1	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	8.59	1	1	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	5.86	3	2	carbazoles
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	8.56	1	1
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	8.59	1	1	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.13	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	4.75	3	0	quinuclidines; saturated organic heterobicyclic parent
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.13	1	0
substance p [no description available]	2.17	1	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	8.59	1	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
repaglinide [no description available]	8.59	1	1	piperidines
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	7.41	1	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	2.13	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
carboplatin [no description available]	8.51	1	1
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	8.56	1	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
granisetron Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.. granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.	5.02	2	1	aromatic amide; indazoles
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	8.59	1	1	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	3.23	1	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
netupitant netupitant: orally active neurokinin-1 receptor antagonist. netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	2.11	1	0	aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes	antiemetic; neurokinin-1 receptor antagonist
cangrelor cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.	2.13	1	0	adenosine 5'-phosphate; aryl sulfide; nucleoside triphosphate analogue; organochlorine compound; organofluorine compound; secondary amino compound	P2Y12 receptor antagonist; platelet aggregation inhibitor
lumacaftor lumacaftor: a corrector of CF transmembrane conductance regulator (CTFR); structure in first source. lumacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis.	2.13	1	0	aromatic amide; benzodioxoles; benzoic acids; cyclopropanes; organofluorine compound; pyridines	CFTR potentiator; orphan drug
piperidines Piperidines: A family of hexahydropyridines.	3.59	1	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.59	1	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	3.93	3	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist

Condition	Indicated	Relationship Strength	Studies	Trials
Cancer of Lung [description not available]	0	2.41	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.41	1	0
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	0	2.41	1	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	0	7.82	2	0
Breast Cancer [description not available]	0	7.41	1	0
Local Neoplasm Recurrence [description not available]	0	2.41	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.41	1	0
Emesis [description not available]	0	13.53	29	11
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	1	18.18	58	22
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	13.53	29	11
Benign Neoplasms [description not available]	0	12.2	17	10
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	12.2	17	10
Liver Dysfunction [description not available]	0	3.56	1	1
Liver Diseases Pathological processes of the LIVER.	0	3.56	1	1
Allergy, Drug [description not available]	0	2.58	2	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	0	2.58	2	0
Adverse Drug Event [description not available]	0	8.12	5	5
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	8.12	5	5
Colitis, Mucous [description not available]	0	2.13	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.13	1	0
Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.	0	2.13	1	0

Intervention	Participants (Count of Participants)
Cohort 1	0
Cohort 2	5

Intervention	proportion of participants (Number)
Sequence A	0.4737
Sequence B	0.4737

Intervention	proportion of participants (Number)
Sequence A	0.6160
Sequence B	0.6842

Intervention	proportion of participants (Number)
Sequence A	0.6000
Sequence B	0.6087

rolapitant

Cross-References

Synonyms (50)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioavailability

Roles (2)

Drug Classes (5)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (68)

Molecular Functions (7)

Ceullar Components (9)

Bioassays (2)

Research

Studies (46)

Market Indicators

Research Demand Index: 46.76

Study Types

Clinical Trials (12)

Trial Overview

Trial Outcomes

Acute Phase Response

No Emetic Episodes and No Rescue Medication

Overall Response Rate

Acute Phase Response

No Emetic Episodes and No Rescue Medication

Overall Response Rate

Acute Phase Response

No Emetic Episodes and No Rescue Medication

Overall Response Rate

Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose

Chemoradiation-induced Nausea (cRIN) Rate Over All Six Weeks

Chemoradiation-induced Nausea (cRIN) Rate Over First Two Weeks

Chemoradiation-induced Nausea (cRIN) Rate Over First Two Weeks and Supplemented by Nurses Notes

Chemoradiation-induced Vomiting (cRIV) Rate Over All Six Weeks

Chemoradiation-induced Vomiting (cRIV) Rate Over First Two Weeks

Chemoradiation-induced Vomiting (cRIV) Rate Over First Two Weeks With Supplemental Nurses Notes

Complete Response (CR) Rate as Measured by Antiemesis Tool (MAT)

Complete Response (CR) Rate as Measured by MAT With Supplemental Nurses Notes

Ondansetron Medication Compliance Weeks 1-3

Ondansetron Medication Compliance Weeks 4-6

Proportion of Participants With Grade 3, 4 or 5 Treatment-related Adverse Events

Week 3 Patient Satisfaction: Convenience

Week 3 Patient Satisfaction: Effectiveness

Week 3 Patient Satisfaction: Overall Satisfaction

Week 6 Patient Satisfaction: Convenience

Week 6 Patient Satisfaction: Effectiveness

Week 6 Patient Satisfaction: Overall Satisfaction

Related Drugs (28)

Related Conditions (21)